Preexisting studies concentrated on the impact of circulating lymphocytes on the survival of CRC patients and their differences from healthy controls [19,20,21,22] or on select subsets, such as NK cells [23] or regulatory CD4+ cells [24]. The gene discussed is CD4; the disease is colorectal carcinoma.